HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TYK MEDICINES-B

6.270

-0.535-7.86%

Volume:26.32M

Turnover:183.97M

Market Cap:2.38B

PE:-6.73

High:8.270

Open:7.825

Low:6.250

Close:6.805

52wk High:22.560

52wk Low:5.350

Shares:380.07M

HK Float Shares:375.46M

Volume Ratio:7.09

T/O Rate:7.01%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.932

ROE:-70.66%

ROA:-28.19%

PB:7.84

PE(LYR):-6.73

PS:19123.95

Loading ...

Overview Company News Filings

TYK Medicines Posts Stable Share Capital and Maintains Public Float in April 2026 Monthly Return

Bulletin Express

TYK Medicines-B 2025年研发推进加速，亏损收窄至3.06亿元，净资产维持正值

Bulletin Express

TYK Medicines publishes 2025 annual report

TYK MEDICINES-B's (02410) Self-Developed TY-3002 Monotherapy Demonstrates Outstanding Weight Loss Efficacy, Pioneering Next-Generation Oral GLP-1R Small Molecule Innovation

TYK Medicines Converts 4.61 Million Unlisted Shares Into H Shares, Registered Capital Rises to RMB 380.07 Million

Bulletin Express

TYK Medicines Completes 4.61 Million-Share Conversion to H Shares, Expanding Registered Capital to 380.07 Million

Bulletin Express

Stock Track | TYK MEDICINES-B Soars 7.26% Intraday on Strong Annual Results and Upcoming AACR Presentation

TYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement

TYK Medicines' Loss Narrows in 2025

MT Newswires Live

BRIEF-Tyk Medicines FY Loss Attributable Rmb299.8 Million

TYK MEDICINES-B Reports Annual Results: R&D Expenditure Rises 3.7% to Approximately 244 Million Yuan

TYK Medicines 2025 Net Loss Narrows 21% to RMB 305.97 Million; NDA for Core Drug TY-9591 Enters Priority Review

Bulletin Express

Tyk Medicines Inc - FY Loss Attributable RMB299.8 Mln

THOMSON REUTERS

TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference

TYK Medicines to present five oncology drug candidates at 2026 AACR Annual Meeting; poster sessions run April 19–21, 2026

TYK Medicines sets board meeting to review 2025 annual results

TYK MEDICINES-B Shares Surge Over 5% Following H-Share Reform Completion and New Drug Application Milestone

TYK MEDICINES-B (02410) Releases Monthly Return for February 2026

Bulletin Express

TYK MEDICINES-B (02410) Announces Completion of H Share Full Circulation

Bulletin Express

TYK MEDICINES-B (Stock Code: 02410) Announces Conversion of 4.61 Million Unlisted Shares to H Shares

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/02410/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02410","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"TYK MEDICINES-B","latestPrice":6.27,"timestamp":1787904513002,"preClose":6.805,"halted":0,"volume":26321500,"delay":0,"changeRate":-0.07861866274797945,"floatShares":375457818,"shares":380065818,"eps":-0.9316546198592012,"marketStatus":"Not Yet Opened","change":-0.535,"latestTime":"08-28 16:08:33","open":7.825,"high":8.27,"low":6.25,"amount":183972620,"amplitude":0.296841,"askPrice":6.28,"askSize":12500,"bidPrice":6.27,"bidSize":47500,"shortable":3,"etf":0,"ttmEps":-0.6539225548377992,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":0,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":6.805,"openAndCloseTimeList":[[1787880600000,1787889600000],[1787893200000,1787904000000]],"volumeRatio":7.0932144011117115,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","floatShares":375457818,"roa":"-28.19%","roe":"-70.66%","lyrEps":-0.931655,"volumeRatio":7.0932144011117115,"shares":380065818,"dividePrice":0,"high":8.27,"amplitude":0.296841,"preClose":6.805,"low":6.25,"week52Low":5.35,"pbRate":"7.84","psRate":"19123.95","week52High":22.56,"institutionHeld":0,"latestPrice":6.27,"committee":0.583333,"eps":-0.9316546198592012,"divideRate":0,"volume":26321500,"delay":0,"ttmEps":-0.6539225548377992,"open":7.825,"prevYearClose":13.11,"prevWeekClose":6.27,"prevMonthClose":6.81,"prevQuarterClose":5.73,"fiveDayClose":6.665,"twentyDayClose":6.81,"sixtyDayClose":8.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02410\",params:#limit:5,,,undefined,":[{"date":"2026-08-17","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1786930200000,"name":null,"time":"","dateTimestamp":1786896000000,"actualEps":null},{"date":"2026-03-30","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-31","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756603800000,"name":null,"time":"","dateTimestamp":1756569600000,"actualEps":null},{"date":"2025-03-27","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743039000000,"name":null,"time":"","dateTimestamp":1743004800000,"actualEps":null},{"date":"2024-08-30","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724981400000,"name":null,"time":"","dateTimestamp":1724947200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02410\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02410\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02410\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02410","date":"2026-08-28","current":-9.588023,"percent":0.873239,"low":-45.171338,"twenty":-23.880566,"median":-17.053511,"eighty":-12.176647,"high":-6.195227,"avg":-18.025321,"sd":7.183078,"marketCap":2411904838},"quantilePoints":[{"date":"2024-08-23","current":-18.036629,"twenty":-16.647141,"median":-14.72623,"eighty":-12.008468,"marketCap":8010053668},{"date":"2024-08-30","current":-17.916348,"twenty":-18.108709,"median":-17.490261,"eighty":-14.277882,"marketCap":8010053668},{"date":"2024-09-06","current":-22.38992,"twenty":-20.387629,"median":-17.957821,"eighty":-15.985061,"marketCap":10531737231},{"date":"2024-09-13","current":-25.215246,"twenty":-24.52304,"median":-18.767123,"eighty":-16.911292,"marketCap":11829662594},{"date":"2024-09-20","current":-22.432724,"twenty":-24.518581,"median":-20.496807,"eighty":-17.208183,"marketCap":10587362603},{"date":"2024-09-27","current":-24.719835,"twenty":-24.497927,"median":-22.38992,"eighty":-17.671485,"marketCap":11736953639},{"date":"2024-10-04","current":-24.95032,"twenty":-24.87878,"median":-23.321155,"eighty":-17.932937,"marketCap":11792579012},{"date":"2024-10-10","current":-25.38933,"twenty":-24.941363,"median":-23.362473,"eighty":-17.973583,"marketCap":11922371548},{"date":"2024-10-18","current":-26.355956,"twenty":-25.311733,"median":-23.798709,"eighty":-18.108709,"marketCap":12311749157},{"date":"2024-10-25","current":-24.571342,"twenty":-25.374683,"median":-24.122054,"eighty":-18.545067,"marketCap":11477368567},{"date":"2024-11-01","current":-18.445843,"twenty":-25.311733,"median":-23.998666,"eighty":-18.584118,"marketCap":8621932768},{"date":"2024-11-08","current":-20.323115,"twenty":-25.278482,"median":-23.623818,"eighty":-17.973583,"marketCap":9456313359},{"date":"2024-11-15","current":-19.45318,"twenty":-25.171449,"median":-23.425489,"eighty":-18.108709,"marketCap":8955685004},{"date":"2024-11-22","current":-24.620137,"twenty":-24.988066,"median":-23.362473,"eighty":-18.406793,"marketCap":11329034239},{"date":"2024-11-29","current":-31.047836,"twenty":-25.311733,"median":-23.554037,"eighty":-18.584118,"marketCap":14277178993},{"date":"2024-12-06","current":-34.758675,"twenty":-25.786797,"median":-23.737743,"eighty":-19.168188,"marketCap":15945940174},{"date":"2024-12-13","current":-35.961329,"twenty":-26.0415,"median":-24.070769,"eighty":-19.324298,"marketCap":16465110319},{"date":"2024-12-20","current":-44.500897,"twenty":-30.298107,"median":-24.44033,"eighty":-19.494791,"marketCap":20284719244},{"date":"2024-12-27","current":-43.273475,"twenty":-31.455257,"median":-24.553474,"eighty":-19.619623,"marketCap":19709923726},{"date":"2025-01-03","current":-39.042242,"twenty":-33.760908,"median":-24.669986,"eighty":-19.709581,"marketCap":17800119264},{"date":"2025-01-10","current":-16.73771,"twenty":-34.083555,"median":-24.719835,"eighty":-19.709581,"marketCap":7602134269},{"date":"2025-01-17","current":-16.071561,"twenty":-33.760908,"median":-24.553474,"eighty":-18.860667,"marketCap":7305465614},{"date":"2025-01-24","current":-20.268382,"twenty":-32.413923,"median":-24.349989,"eighty":-19.230133,"marketCap":9270895450},{"date":"2025-01-28","current":-18.549699,"twenty":-31.591026,"median":-24.122054,"eighty":-18.549699,"marketCap":8529223814},{"date":"2025-02-07","current":-17.965815,"twenty":-31.472067,"median":-23.871541,"eighty":-18.275892,"marketCap":8214013368},{"date":"2025-02-14","current":-19.878813,"twenty":-31.451054,"median":-23.623818,"eighty":-18.275892,"marketCap":9066935750},{"date":"2025-02-21","current":-25.066745,"twenty":-31.047836,"median":-23.789321,"eighty":-18.32609,"marketCap":11495910358},{"date":"2025-02-28","current":-26.244856,"twenty":-30.411824,"median":-23.765234,"eighty":-18.39703,"marketCap":11996538712},{"date":"2025-03-07","current":-24.725844,"twenty":-30.135297,"median":-23.927628,"eighty":-18.445843,"marketCap":11347576030},{"date":"2025-03-14","current":-23.101371,"twenty":-29.84324,"median":-23.977848,"eighty":-18.549699,"marketCap":10605904394},{"date":"2025-03-21","current":-22.868028,"twenty":-28.789228,"median":-23.789321,"eighty":-18.691799,"marketCap":10494653649},{"date":"2025-03-28","current":-28.703724,"twenty":-28.703724,"median":-23.977848,"eighty":-19.110968,"marketCap":13146129748},{"date":"2025-04-03","current":-29.204856,"twenty":-29.744706,"median":-24.122054,"eighty":-19.131966,"marketCap":12070705875},{"date":"2025-04-11","current":-24.387234,"twenty":-29.307899,"median":-24.067881,"eighty":-19.145106,"marketCap":10012567086},{"date":"2025-04-17","current":-24.599189,"twenty":-28.955479,"median":-24.067881,"eighty":-19.224594,"marketCap":10123817831},{"date":"2025-04-25","current":-24.758022,"twenty":-28.755026,"median":-24.236021,"eighty":-19.282593,"marketCap":10197984995},{"date":"2025-05-02","current":-30.859428,"twenty":-28.772127,"median":-24.368612,"eighty":-19.308976,"marketCap":12738210348},{"date":"2025-05-09","current":-26.222368,"twenty":-28.789228,"median":-24.487968,"eighty":-19.376573,"marketCap":11477368567},{"date":"2025-05-16","current":-19.875071,"twenty":-28.703724,"median":-24.44033,"eighty":-19.45318,"marketCap":8770267095},{"date":"2025-05-23","current":-18.391406,"twenty":-28.460584,"median":-24.320388,"eighty":-19.147078,"marketCap":8139846205},{"date":"2025-05-30","current":-16.767615,"twenty":-28.328721,"median":-24.116277,"eighty":-18.777931,"marketCap":7453799941},{"date":"2025-06-06","current":-19.720458,"twenty":-27.077703,"median":-23.93026,"eighty":-18.847277,"marketCap":8788808886},{"date":"2025-06-13","current":-16.18601,"twenty":-26.697665,"median":-23.850097,"eighty":-18.709822,"marketCap":7216465018},{"date":"2025-06-20","current":-14.05098,"twenty":-26.664525,"median":-23.778892,"eighty":-18.426653,"marketCap":6252291891},{"date":"2025-06-27","current":-16.3221,"twenty":-26.630078,"median":-23.66211,"eighty":-18.32609,"marketCap":7283215465},{"date":"2025-07-04","current":-17.493079,"twenty":-26.41078,"median":-23.623818,"eighty":-18.194509,"marketCap":7806093968},{"date":"2025-07-11","current":-16.487526,"twenty":-26.267076,"median":-23.430941,"eighty":-17.964216,"marketCap":7349965912},{"date":"2025-07-18","current":-15.867745,"twenty":-26.226866,"median":-23.321155,"eighty":-17.866761,"marketCap":7068130691},{"date":"2025-07-25","current":-16.407488,"twenty":-26.143659,"median":-23.070409,"eighty":-17.335488,"marketCap":7335132480},{"date":"2025-08-01","current":-14.539711,"twenty":-26.072617,"median":-22.868028,"eighty":-17.325642,"marketCap":6459959949},{"date":"2025-08-08","current":-15.316665,"twenty":-25.987382,"median":-22.563641,"eighty":-17.04089,"marketCap":6822181433},{"date":"2025-08-15","current":-17.450454,"twenty":-25.968574,"median":-22.406203,"eighty":-16.915178,"marketCap":7760944003},{"date":"2025-08-22","current":-13.484776,"twenty":-25.95357,"median":-22.354126,"eighty":-16.718364,"marketCap":5978435317},{"date":"2025-08-29","current":-12.516323,"twenty":-25.925655,"median":-21.46252,"eighty":-16.486483,"marketCap":5575565550},{"date":"2025-09-05","current":-19.23268,"twenty":-25.919389,"median":-21.226743,"eighty":-16.486483,"marketCap":5883418862},{"date":"2025-09-12","current":-18.156363,"twenty":-25.850806,"median":-20.678772,"eighty":-16.541494,"marketCap":5564163575},{"date":"2025-09-19","current":-18.839434,"twenty":-25.807696,"median":-20.500943,"eighty":-16.56352,"marketCap":5769399117},{"date":"2025-09-26","current":-19.348832,"twenty":-25.743581,"median":-20.268382,"eighty":-16.654406,"marketCap":5910023469},{"date":"2025-10-03","current":-22.468168,"twenty":-25.650075,"median":-20.314843,"eighty":-16.707921,"marketCap":6879191305},{"date":"2025-10-10","current":-19.927643,"twenty":-25.596841,"median":-20.323115,"eighty":-16.732368,"marketCap":6092455062},{"date":"2025-10-17","current":-19.134493,"twenty":-25.519561,"median":-20.155539,"eighty":-16.749672,"marketCap":5845412280},{"date":"2025-10-24","current":-17.635142,"twenty":-25.404318,"median":-19.980008,"eighty":-16.781291,"marketCap":5389333299},{"date":"2025-10-31","current":-19.024541,"twenty":-25.400784,"median":-19.927643,"eighty":-16.830147,"marketCap":5822608331},{"date":"2025-11-07","current":-17.694439,"twenty":-25.37593,"median":-19.869193,"eighty":-16.945559,"marketCap":5412137248},{"date":"2025-11-14","current":-17.099248,"twenty":-25.321084,"median":-19.741813,"eighty":-16.951188,"marketCap":5244908288},{"date":"2025-11-21","current":-15.19815,"twenty":-25.311733,"median":-19.694587,"eighty":-16.919035,"marketCap":4659606928},{"date":"2025-11-28","current":-16.711808,"twenty":-25.293455,"median":-19.641679,"eighty":-16.730587,"marketCap":5142290517},{"date":"2025-12-05","current":-17.262657,"twenty":-25.275139,"median":-19.635782,"eighty":-16.587841,"marketCap":5320921452},{"date":"2025-12-12","current":-16.160016,"twenty":-25.213434,"median":-19.544821,"eighty":-16.497144,"marketCap":4990264190},{"date":"2025-12-19","current":-16.355316,"twenty":-25.19336,"median":-19.414876,"eighty":-16.454475,"marketCap":5062476695},{"date":"2025-12-24","current":-15.692499,"twenty":-25.154877,"median":-19.348832,"eighty":-16.406101,"marketCap":4872443786},{"date":"2026-01-02","current":-15.765099,"twenty":-25.10227,"median":-19.292077,"eighty":-16.35327,"marketCap":4914251026},{"date":"2026-01-09","current":-17.392186,"twenty":-25.070347,"median":-19.235279,"eighty":-16.345574,"marketCap":5434941197},{"date":"2026-01-16","current":-16.438751,"twenty":-25.06473,"median":-19.137216,"eighty":-16.35327,"marketCap":5153692492},{"date":"2026-01-23","current":-15.75073,"twenty":-25.023112,"median":-19.120814,"eighty":-16.314941,"marketCap":4933254317},{"date":"2026-01-30","current":-15.280433,"twenty":-24.971672,"median":-19.022068,"eighty":-16.22453,"marketCap":4807832597},{"date":"2026-02-06","current":-15.542994,"twenty":-24.952303,"median":-18.937078,"eighty":-16.152588,"marketCap":4902849052},{"date":"2026-02-13","current":-15.334427,"twenty":-24.923448,"median":-18.860882,"eighty":-16.099082,"marketCap":4864842470},{"date":"2026-02-20","current":-15.572498,"twenty":-24.905533,"median":-18.847277,"eighty":-16.071561,"marketCap":4933254317},{"date":"2026-02-27","current":-14.952615,"twenty":-24.827654,"median":-18.801141,"eighty":-15.988536,"marketCap":4788829306},{"date":"2026-03-06","current":-13.279596,"twenty":-24.77147,"median":-18.709822,"eighty":-15.892604,"marketCap":4218730579},{"date":"2026-03-13","current":-12.861452,"twenty":-24.760877,"median":-18.616931,"eighty":-15.828013,"marketCap":4104710834},{"date":"2026-03-20","current":-12.157235,"twenty":-24.758022,"median":-18.440891,"eighty":-15.765099,"marketCap":3865269369},{"date":"2026-03-27","current":-12.164275,"twenty":-24.758022,"median":-18.409208,"eighty":-15.692499,"marketCap":3857668052},{"date":"2026-04-02","current":-12.25818,"twenty":-24.73228,"median":-18.399621,"eighty":-15.606124,"marketCap":4180723998},{"date":"2026-04-10","current":-12.412577,"twenty":-24.72344,"median":-18.391406,"eighty":-15.554796,"marketCap":4266032641},{"date":"2026-04-17","current":-12.351427,"twenty":-24.717087,"median":-18.309793,"eighty":-15.461655,"marketCap":4246798950},{"date":"2026-04-24","current":-11.422185,"twenty":-24.709149,"median":-18.216326,"eighty":-15.337994,"marketCap":3927519681},{"date":"2026-04-30","current":-11.117278,"twenty":-24.702871,"median":-18.174743,"eighty":-15.304685,"marketCap":3823657750},{"date":"2026-05-08","current":-10.777891,"twenty":-24.684547,"median":-18.056929,"eighty":-15.189837,"marketCap":3719795820},{"date":"2026-05-15","current":-9.293361,"twenty":-24.617578,"median":-17.965815,"eighty":-15.119492,"marketCap":3215873118},{"date":"2026-05-22","current":-8.991533,"twenty":-24.605712,"median":-17.939574,"eighty":-15.043492,"marketCap":3104317711},{"date":"2026-05-29","current":-10.14843,"twenty":-24.599189,"median":-17.918048,"eighty":-14.961326,"marketCap":3515918696},{"date":"2026-06-05","current":-8.237808,"twenty":-24.571342,"median":-17.89208,"eighty":-14.895383,"marketCap":2858126467},{"date":"2026-06-12","current":-7.644268,"twenty":-24.535606,"median":-17.732128,"eighty":-14.684931,"marketCap":2650402606},{"date":"2026-06-18","current":-6.884404,"twenty":-24.459385,"median":-17.688347,"eighty":-14.384241,"marketCap":2392671147},{"date":"2026-06-26","current":-6.195227,"twenty":-24.397853,"median":-17.672452,"eighty":-13.470121,"marketCap":2142633166},{"date":"2026-07-03","current":-7.179757,"twenty":-24.364887,"median":-17.499062,"eighty":-13.369605,"marketCap":2484992864},{"date":"2026-07-10","current":-8.078806,"twenty":-24.314468,"median":-17.476751,"eighty":-13.262753,"marketCap":2792731918},{"date":"2026-07-17","current":-8.127776,"twenty":-24.232724,"median":-17.419476,"eighty":-13.079412,"marketCap":2819659085},{"date":"2026-07-24","current":-7.604914,"twenty":-24.150839,"median":-17.377721,"eighty":-12.93356,"marketCap":2638862391},{"date":"2026-07-31","current":-7.53517,"twenty":-24.119743,"median":-17.333807,"eighty":-12.87079,"marketCap":2619628700},{"date":"2026-08-07","current":-7.625479,"twenty":-24.07756,"median":-17.320685,"eighty":-12.528428,"marketCap":2656172713},{"date":"2026-08-14","current":-7.417307,"twenty":-24.00283,"median":-17.276309,"eighty":-12.375887,"marketCap":2586931426},{"date":"2026-08-21","current":-10.34776,"twenty":-23.939778,"median":-17.197085,"eighty":-12.303816,"marketCap":2563850996},{"date":"2026-08-28","current":-9.732294,"twenty":-23.880566,"median":-17.053511,"eighty":-12.176647,"marketCap":2411904838}],"updateTime":1788130249655},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02410\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1169008621","title":"TYK Medicines Posts Stable Share Capital and Maintains Public Float in April 2026 Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1169008621","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169008621?lang=en_us&edition=fundamental","pubTime":"2026-05-06 17:23","pubTimestamp":1778059403,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (H-share; HKEX: 02410) filed its Monthly Return for Equity Issuer covering the period ended 30 April 2026, confirming no changes to share capital and continued compliance with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120304539","title":"TYK Medicines-B 2025年研发推进加速，亏损收窄至3.06亿元，净资产维持正值","url":"https://stock-news.laohu8.com/highlight/detail?id=1120304539","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120304539?lang=en_us&edition=fundamental","pubTime":"2026-04-29 16:59","pubTimestamp":1777453145,"startTime":"0","endTime":"0","summary":"TYK Medicines-B于本年度进一步聚焦癌症领域的差异化创新靶向治疗，专注于小分子抗肿瘤药物的研发与商业化推进，共拥有10项在研新药，其中5款处于临床阶段，4款处于临床前或早期临床阶段。核心产品TY-9591围绕EGFR基因突变相关的非小细胞肺癌展开多项临床试验，涵盖针对脑转移的一线单药治疗、与培美曲塞及顺铂或卡铂联合用药的二、三期试验及EGFR...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"TYK Medicines-B 2025年研发推进加速，亏损收窄至3.06亿元，净资产维持正值","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631560423","title":"TYK Medicines publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631560423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631560423?lang=en_us&edition=fundamental","pubTime":"2026-04-29 16:43","pubTimestamp":1777452198,"startTime":"0","endTime":"0","summary":"TYK Medicines annual report for 2025 outlined progress toward first commercialization, led by core oncology asset TY-9591.TY-9591 conditional NDA for first-line treatment of brain metastases in EGFR-mutant lung cancer entered priority review in January 2026, with marketing approval expected in Q3 2026.Enrollment in registrational Phase III trial of TY-9591 in first-line EGFR L858R-mutant NSCLC reached 548 patients in April 2026, with full enrollment expected in Q4 2026 and NDA targeted for 2028.Pipeline execution extended beyond TY-9591, with TY-302 in Phase II for breast cancer, TY-2136b in Phase I in US, TY-1054 dosing first patient in March 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the origina","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL4lSxhd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181264075","title":"TYK MEDICINES-B's (02410) Self-Developed TY-3002 Monotherapy Demonstrates Outstanding Weight Loss Efficacy, Pioneering Next-Generation Oral GLP-1R Small Molecule Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=1181264075","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181264075?lang=en_us&edition=fundamental","pubTime":"2026-04-16 17:13","pubTimestamp":1776330825,"startTime":"0","endTime":"0","summary":"The weight loss sector, a core focus in global innovative drug development, continues to attract leading industry players. Recently, TYK MEDICINES-B (02410) announced the formal nomination of its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","159938","GLP","BK1574","09939","BK4144","TY","02410","BK4590","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116554785","title":"TYK Medicines Converts 4.61 Million Unlisted Shares Into H Shares, Registered Capital Rises to RMB 380.07 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1116554785","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116554785?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:02","pubTimestamp":1775642537,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (TYK Medicines) reported in its resubmitted Monthly Return for the period ended 31 March 2026 that it completed the conversion of 4.61 million unlisted shares into the same number...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136728831","title":"TYK Medicines Completes 4.61 Million-Share Conversion to H Shares, Expanding Registered Capital to 380.07 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136728831","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136728831?lang=en_us&edition=fundamental","pubTime":"2026-04-02 16:44","pubTimestamp":1775119481,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. released its Monthly Return on Movements in Securities for March 2026, highlighting a structural change in its share composition: • Share Class Conversion: On 4 March 2026, the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182188038","title":"Stock Track | TYK MEDICINES-B Soars 7.26% Intraday on Strong Annual Results and Upcoming AACR Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=1182188038","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182188038?lang=en_us&edition=fundamental","pubTime":"2026-04-01 12:57","pubTimestamp":1775019445,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B's stock surged 7.26% during intraday trading on Wednesday, driven by the release of its annual financial results and a significant research announcement.The company recently disclosed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153741167","title":"TYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1153741167","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153741167?lang=en_us&edition=fundamental","pubTime":"2026-04-01 12:02","pubTimestamp":1775016153,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) saw its shares rise more than 7%. As of the time of writing, the stock was up 7.07%, trading at HKD 10.9 with a turnover of HKD 30.54 million. On March 31, TYK MEDICINES-B...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","159938","159992","BK1515","09939","06978","BK1574","02410","BK1161","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623720553","title":"TYK Medicines' Loss Narrows in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2623720553","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623720553?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:39","pubTimestamp":1774931956,"startTime":"0","endTime":"0","summary":"TYK Medicines'  loss attributable to owners narrowed to 299.8 million yuan for 2025, from 387 million yuan a year earlier, according to a Monday Hong Kong bourse filing.Shares of the pharmaceutical company were up nearly 2% in late morning trade on Tuesday.Loss per share shrank to 0.80 yuan from 1.15 yuan a year earlier.The company did not generate revenue in 2025. In 2024, its revenue came in at 107,000 yuan.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02410","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623231904","title":"BRIEF-Tyk Medicines FY Loss Attributable Rmb299.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623231904","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623231904?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:57","pubTimestamp":1774868230,"startTime":"0","endTime":"0","summary":"BRIEF-Tyk Medicines FY Loss Attributable Rmb299.8 MillionMarch 30 (Reuters) - TYK Medicines Inc 2410.HK:FY LOSS ATTRIBUTABLE RMB299.8 MILLIONFurther company coverage: 2410.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40G02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108363335","title":"TYK MEDICINES-B Reports Annual Results: R&D Expenditure Rises 3.7% to Approximately 244 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1108363335","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108363335?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:06","pubTimestamp":1774861599,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) has announced its financial results for the fiscal year ended December 31, 2025. The company's research and development costs amounted to approximately 244 million yuan,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1574","BK1515","159938","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124616055","title":"TYK Medicines 2025 Net Loss Narrows 21% to RMB 305.97 Million; NDA for Core Drug TY-9591 Enters Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1124616055","media":"Bulletin Express","labels":["productRelease","dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124616055?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:05","pubTimestamp":1774861549,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. reported a consolidated net loss of RMB 305.97 million for 2025, an improvement of 21.1% versus 2024. Loss per share narrowed to RMB 0.80 from RMB 1.15. R&D AND EXPENSES   •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623909413","title":"Tyk Medicines Inc - FY Loss Attributable RMB299.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623909413","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623909413?lang=en_us&edition=fundamental","pubTime":"2026-03-30 16:45","pubTimestamp":1774860342,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40G02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106629682","title":"TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1106629682","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106629682?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:44","pubTimestamp":1774449860,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","159992","09939","02410","159938","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072480","title":"TYK Medicines to present five oncology drug candidates at 2026 AACR Annual Meeting; poster sessions run April 19–21, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072480","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072480?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:38","pubTimestamp":1774449530,"startTime":"0","endTime":"0","summary":"TYK Medicines said research progress and results for five innovative drug projects—TY-0609 , TY-2699a , TY-2719 , PI3Kα , and TY-1054 —will be presented at the 2026 American Association for Cancer Research annual meeting.The poster presentations are scheduled for April 19 to April 21, 2026, at the meeting in San Diego, which runs from April 17 to 22, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL83cl9c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620356032","title":"TYK Medicines sets board meeting to review 2025 annual results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620356032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620356032?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:35","pubTimestamp":1773822945,"startTime":"0","endTime":"0","summary":"TYK Medicines will hold a board meeting on March 30, 2026 to consider and approve its annual results for the year ended December 31, 2025. The board will also consider the payment of a final dividend, if any, at the March 30, 2026 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7xlNVB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133725281","title":"TYK MEDICINES-B Shares Surge Over 5% Following H-Share Reform Completion and New Drug Application Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=1133725281","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133725281?lang=en_us&edition=fundamental","pubTime":"2026-03-06 12:01","pubTimestamp":1772769706,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) rose more than 5%, with a gain of 4.92% at the time of writing to HK$11.34, generating a turnover of HK$27.5877 million. On March 4, the company announced that the conversion...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1515","09939","BK4585","VT","159938","VXUS","BK1574","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165073169","title":"TYK MEDICINES-B (02410) Releases Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1165073169","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165073169?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:17","pubTimestamp":1772615856,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) released its Monthly Return on Movements in Securities for the period ended 28 February 2026. According to the announcement, the registered H shares remained at 375,457,818,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110993136","title":"TYK MEDICINES-B (02410) Announces Completion of H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1110993136","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110993136?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:17","pubTimestamp":1772615837,"startTime":"0","endTime":"0","summary":"TYK Medicines-B (02410) announced the completion of its H share full circulation process on March 4, 2026. According to the announcement, 4.61 million unlisted shares were successfully converted into...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102975301","title":"TYK MEDICINES-B (Stock Code: 02410) Announces Conversion of 4.61 Million Unlisted Shares to H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1102975301","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102975301?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:15","pubTimestamp":1772615739,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (Stock Code: 02410) disclosed that as of 28 February 2026, the company had approximately 375.46 million H shares. On 4 March 2026, 4.61 million unlisted shares were converted into H...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":62,"code":"91000000","status":"200"}]}}